Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRCA2-associated Malignancies”

18 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 18 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT02393794
What this trial is testing

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Who this might be right for
Triple-Negative Breast CancerBreast Cancer
Priyanka Sharma 51
Testing effectiveness (Phase 2)Study completedNCT00677079
What this trial is testing

Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Primary Peritoneal CancerAdvanced Epithelial Ovarian Cancer
Sanofi 12
Not applicableStudy completedNCT05305001
What this trial is testing

Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico

Who this might be right for
Pancreatic CancerPancreatic Adenocarcinoma
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 107
Early research (Phase 1)Ended earlyNCT04598321
What this trial is testing

BrUOG 390: Neoadjuvant Treatment With Talazoparib

Who this might be right for
BRCA1 MutationBRCA2 MutationOvarian Cancer+2 more
Brown University 1
Testing effectiveness (Phase 2)Study completedNCT00494442
What this trial is testing

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

Who this might be right for
Ovarian Neoplasm
AstraZeneca 58
Large-scale testing (Phase 3)Study completedNCT02163694
What this trial is testing

Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AbbVie 513
Early research (Phase 1)Looking for participantsNCT06488378
What this trial is testing

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Who this might be right for
Breast CancerPALB2-Mutated Breast CarcinomaHER2-negative Breast Cancer+2 more
Dana-Farber Cancer Institute 20
Testing effectiveness (Phase 2)Looking for participantsNCT05485766
What this trial is testing

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsTriple Negative Breast CancerBreast Neoplasms+5 more
Okayama University 23
Early research (Phase 1)Study completedNCT03685331
What this trial is testing

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerAdvanced Breast Cancer+2 more
Abramson Cancer Center at Penn Medicine 9
Testing effectiveness (Phase 2)Study completedNCT00628251
What this trial is testing

Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
AstraZeneca 97
Not applicableNo Longer AvailableNCT02985658
What this trial is testing

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic MutationTriple-Negative Breast Cancer
University of Washington
Early research (Phase 1)Study completedNCT01104259
What this trial is testing

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerHereditary Breast/Ovarian Cancer - BRCA1+6 more
University of Washington 50
Testing effectiveness (Phase 2)Study completedNCT00494234
What this trial is testing

Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
AstraZeneca 54
Not applicableLooking for participantsNCT01034033
What this trial is testing

Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples

Who this might be right for
Breast CancerOvarian CancerGynecologic Cancers+1 more
Stanford University 3,300
Not applicableStudy completedNCT00040222
What this trial is testing

Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

Who this might be right for
Familial Ovarian CancerFamilial Breast CancerBRCA1-associate Malignancies+1 more
National Cancer Institute (NCI) 377
Early research (Phase 1)Looking for participantsNCT04890613
What this trial is testing

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Who this might be right for
Advanced Solid Tumor
Senhwa Biosciences, Inc. 52
Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Testing effectiveness (Phase 2)WithdrawnNCT05209529
What this trial is testing

Chemo-free BRCA-targeted Neoadjuvant Strategy

Who this might be right for
TNBC - Triple-Negative Breast CancerBRCA1 MutationBRCA2 Mutation
European Organisation for Research and Treatment of Cancer - EORTC